cbdMD shares surge 63.42% intraday after launching integrated regulatory science program with Bluebird Botanicals acquisition.

cbdMD, Inc. (NYSE American:YCBD) surged 63.42% intraday following its announcement of a strategic regulatory science initiative and the acquisition of Bluebird Botanicals. The company integrated Bluebird’s self-affirmed GRAS determination for full-spectrum hemp extract and aims to strengthen its regulatory platform, positioning itself for evolving federal oversight. The acquisition, expected to drive 10% revenue growth, and the launch of a comprehensive safety and regulatory program were highlighted as key catalysts. Ronan Kennedy, CEO, emphasized the initiative’s role in preparing for future regulatory scrutiny, aligning with the stock’s sharp intraday rally despite prior week-long volatility. The move reflects investor optimism over cbdMD’s strategic expansion and regulatory preparedness in the hemp-derived wellness sector.